Please login to the form below

Not currently logged in
Email:
Password:

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

Valeant adds Jeffrey Ubben to boardValeant has appointed Jeffrey Ubben, CEO of ValueAct Capital, as a member of its board of directors.

Ubben joins at a crucial time for Valeant as the company tries to take over Allergan, the marketer of Botox and other aesthetic and health products.

The company will benefit from Ubben's rich business experience, which includes founding the investment management firm ValueAct Capital.

Ubben commented on the recent attempts to acquire Allergan, which have prompted a backlash, with Allergan questioning Valeant's business model.

“Valeant has become significantly undervalued on a standalone basis due to recent unjustified attacks on the company,” said Ubben. “We are strongly supportive of the Allergan-Valeant combination in light of their perfect strategic fit and the potential to create enormous shareholder value for both companies.”

2nd October 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics